Literature DB >> 12183431

Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Donald R Schwartz1, Sharon L R Kardia, Kerby A Shedden, Rork Kuick, George Michailidis, Jeremy M G Taylor, David E Misek, Rong Wu, Yali Zhai, Danielle M Darrah, Heather Reed, Lora H Ellenson, Thomas J Giordano, Eric R Fearon, Samir M Hanash, Kathleen R Cho.   

Abstract

Biologically and clinically meaningful tumor classification schemes have long been sought. Some malignant epithelial neoplasms, such as those in the thyroid and endometrium, exhibit more than one pattern of differentiation, each associated with distinctive clinical features and treatments. In other tissues, all carcinomas, regardless of morphological type, are treated as though they represent a single disease. To better understand the biological and clinical features seen in the four major histological types of ovarian carcinoma (OvCa), we analyzed gene expression in 113 ovarian epithelial tumors using oligonucleotide microarrays. Global views of the variation in gene expression were obtained using PCA. These analyses show that mucinous and clear cell OvCas can be readily distinguished from serous OvCas based on their gene expression profiles, regardless of tumor stage and grade. In contrast, endometrioid adenocarcinomas show significant overlap with other histological types. Although high-stage/grade tumors are generally separable from low-stage/grade tumors, clear cell OvCa has a molecular signature that distinguishes it from other poor-prognosis OvCas. Indeed, 73 genes, expressed 2- to 29-fold higher in clear cell OvCas compared with each of the other OvCa types, were identified. Collectively, the data indicate that gene expression patterns in ovarian adenocarcinomas reflect both morphological features and biological behavior. Moreover, these studies provide a foundation for the development of new type-specific diagnostic strategies and treatments for ovarian cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12183431

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  138 in total

1.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

Authors:  Akira Tsuchiya; Michiie Sakamoto; Jun Yasuda; Makoto Chuma; Tsutomu Ohta; Misao Ohki; Toshiharu Yasugi; Yuji Taketani; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

3.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

4.  Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.

Authors:  Claudia Fredolini; Francesco Meani; Alessandra Luchini; Weidong Zhou; Paul Russo; Mark Ross; Alexis Patanarut; Davide Tamburro; Guido Gambara; David Ornstein; Franco Odicino; Monica Ragnoli; Antonella Ravaggi; Francesco Novelli; Devis Collura; Leonardo D'Urso; Giovanni Muto; Claudio Belluco; Sergio Pecorelli; Lance Liotta; Emanuel F Petricoin
Journal:  AAPS J       Date:  2010-06-12       Impact factor: 4.009

5.  Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Authors:  Astrid M Eder; Xiaomei Sui; Daniel G Rosen; Laura K Nolden; Kwai Wa Cheng; John P Lahad; Madhuri Kango-Singh; Karen H Lu; Carla L Warneke; Edward N Atkinson; Isabelle Bedrosian; Khandan Keyomarsi; Wen-lin Kuo; Joe W Gray; Jerry C P Yin; Jinsong Liu; Georg Halder; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

Review 6.  Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Authors:  Manfred Dietel; Christine Sers
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 7.  Proteomic profiling in ovarian cancer.

Authors:  Geoffrey Kim; Lucas Minig; Elise C Kohn
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

8.  Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

Authors:  Tanja Pejovic; Nupur T Pande; Motomi Mori; Paulette Mhawech-Fauceglia; Christina Harrington; Solange Mongoue-Tchokote; Daniel Dim; Christopher Andrews; Amy Beck; Yukie Tarumi; Jovana Djilas; Fabio Cappuccini; Otavia Caballero; Jiaqi Huang; Samuel Levy; Alexia Tsiamouri; Joanna Cain; Grover C Bagby; Robert L Strausberg; Andrew J Simpson; Kunle O Odunsi
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

9.  Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice.

Authors:  Chad Creighton; Rork Kuick; David E Misek; David S Rickman; Franck M Brichory; Jean-Marie Rouillard; Gilbert S Omenn; Samir Hanash
Journal:  Genome Biol       Date:  2003-06-23       Impact factor: 13.583

10.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.